XJN010 nasal spray for treating off episodes in Parkinson's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled Phase 2 trial of XJN010 nasal spray in people with Parkinson's disease who experience off episodes. A total of 84 eligible participants were enrolled and treated over a 14-day period (Day 1 to Day 14). Participants were assigned in cohorts to receive XJN010 or matching placebo with a 3:1 randomization within dose groups. Safety, pharmacokinetics, pharmacodynamics, and efficacy outcomes were collected during the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients aged 30 to 85 years (inclusive);
* Diagnosed with Parkinson's disease according to the Chinese Diagnostic Criteria for Parkinson's Disease (2016), with a disease duration of at least 3 years;
* Patients with a Hoehn-Yahr stage rating (during "on" periods) of 1 to 3;
* Demonstrates responsiveness to levodopa (≥30% improvement/decrease in UPDRS-III score (motor examination) from "off" to "on" state following morning administration of routine levodopa dose);
* Patients must have no plans for conception from 2 weeks before the first dose until 1 month after the last dose, no plans to donate sperm, and agree to use highly effective contraception methods;
* Patients are capable of understanding the study requirements, voluntarily provide written informed consent, and are able to complete the study in compliance with the trial protocol.

Exclusion Criteria:

* Individuals with motor impairments that severely affect their ability to participate in and perform study procedures;
* Those exhibiting dyskinesia that significantly impacts daily functioning;
* Known hypersensitivity/allergic reaction or intolerance to any component of the investigational drug;
* Previous Parkinson's disease (PD) surgery (including but not limited to deep brain stimulation or brain cell transplantation) or planned PD surgery during the trial period;
* History of malignancy within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, or ductal carcinoma in situ of the breast treated with radical surgery;
* History of severe psychiatric disorders within the past year, such as major depression, mania, schizophrenia, or patients with suicidal tendencies;
* Patients deemed unsuitable for intranasal administration by the investigator (e.g., severe rhinitis, nasal deformities, etc.);
* Those currently receiving centrally nervous system-active medications (e.g., sedatives, hypnotics, antidepressants, anxiolytics), except for those who have maintained a stable dose for at least 30 days prior to screening and can remain stable during the study;
* History of orthostatic hypotension or clinically significant hypotension or orthostatic hypotension identified during screening (orthostatic hypotension is defined as a drop in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within 3 minutes of standing from a supine position)
* Any laboratory test during screening meeting the following criteria:

Liver function: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN); or total bilirubin \>2 × ULN; Renal function: Serum creatinine \>178 μmol/L;11. Pregnant or lactating females, or those with a positive pregnancy test during screening;

* History of drug or alcohol abuse within the past year;
* Participation in a clinical trial and use of an investigational drug within 1 month prior to screening or within 5 drug half-lives (whichever is longer);
* Any other condition considered by the investigator to make the patient unsuitable for participation in the trial.

Where it's running

• The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: HuaLiang Liu, Master
• Email: liuhl@gznovaken.com
• Phone: +86+13590957282

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions

  A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07883720

• Tributyrin for PSP: a virtual, early-phase study

  This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.

  Recruiting Phase 1/2 University of Michigan · Ann Arbor, Michigan · NCT07863180

• A look at why Lewy body conditions cause visual hallucinations

  This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.

  Recruiting NYU Langone Health · New York, New York · NCT07849413

• How physical activity might help people with Parkinson’s disease who have DBS-STN implants

  This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.

  Recruiting Medical University of Warsaw · Warsaw · NCT07838636

• Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?

  This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.

  Recruiting Klinik Valens · Valens, Canton of St. Gallen · NCT07802509

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.